abrdn World Healthcare Fund
Sponsor: abrdn · Inception Jun 26, 2015 · Pays monthly
Market priceShare price
$12.22
+2.35% (+$0.28)
NAVAsset value per share
$12.40
as of Oct 13, 2026 · Nasdaq NAV symbol
Premium / discountPrice vs. assets
1.45% discount *
Indicative: latest price vs latest reported NAV
Distribution rate (price)Payout rate
10.80%
regular, annualised · on NAV 10.65%
Expense ratioAnnual cost
3.00%
fee table, May 15, 2026
LeverageBorrowing
14.8%
of total managed assets
Quote status: Market closed — last regular-session price · last trade Oct 15, 2026, 4:00 PM EDT (exchange time, ET) · retrieved Oct 15, 2026, 5:46 PM EDTRegular-session prices; extended-hours quotes are not displayed.
Full portfolio as filed on SEC Form N-PORT for the month ending Jun 30, 2026, filed Aug 28, 2026. 131 positions; weights are percent of net assets as reported. Weights sum to 100.0% — leverage, cash, derivatives and short positions mean totals need not equal 100%. This is a historical report, not a live portfolio.
Top 10 holdings
| # | Security | Type | Country | Weight | Value (USD) |
|---|---|---|---|---|---|
| 1 | uniQure NV | Equity | Netherlands | 5.30% | $36.5M |
| 2 | AstraZeneca PLC | Equity | United Kingdom | 4.00% | $27.5M |
| 3 | VeraDermics Inc | Equity | United States | 3.45% | $23.8M |
| 4 | Abivax SA | Equity | France | 3.28% | $22.6M |
| 5 | Sanofi SA | Equity | France | 2.92% | $20.1M |
| 6 | VERADERMICS, INC. | Preferred | United States | 2.65% | $18.2M |
| 7 | Argenx SE | Equity | Netherlands | 2.59% | $17.9M |
| 8 | Novo Nordisk A/S | Equity | Denmark | 2.56% | $17.6M |
| 9 | Abbott Laboratories | Equity | United States | 2.40% | $16.5M |
| 10 | UnitedHealth Group Inc | Equity | United States | 2.30% | $15.8M |
Asset class
| Asset class | % net assets | Value |
|---|---|---|
| Equity (common) | 84.02% | $579M |
| Debt | 6.98% | $48.1M |
| Equity (preferred) | 5.36% | $36.9M |
| Derivative (equity) | 2.87% | $19.7M |
| Short-term investment vehicle | 0.70% | $4.8M |
| Derivative (FX) | 0.08% | $582K |
Country (top 12)
| Country (top 12) | % net assets | Value |
|---|---|---|
| France | 7.71% | $53.1M |
| United Kingdom | 7.29% | $50.3M |
| Switzerland | 6.38% | $44M |
| United States | 53.93% | $372M |
| Ireland | 3.62% | $25M |
| Cayman Islands | 3.22% | $22.2M |
| Denmark | 2.87% | $19.8M |
| Netherlands | 12.16% | $83.8M |
| Germany | 0.98% | $6.7M |
| Belgium | 0.59% | $4.1M |
| Finland | 0.52% | $3.6M |
| Israel | 0.34% | $2.3M |
Region
| Region | % net assets | Value |
|---|---|---|
| United States | 53.93% | $372M |
| Developed Europe | 42.24% | $291M |
| Offshore domiciles | 3.22% | $22.2M |
| Middle East | 0.34% | $2.3M |
| Asia ex-Japan | 0.27% | $1.8M |
| Other | 0.00% | $18.1K |
| Canada | 0.00% | $5.1K |
Issuer type
| Issuer type | % net assets | Value |
|---|---|---|
| Corporate | 91.48% | $630M |
| Other | 7.82% | $53.9M |
| Registered fund | 0.70% | $4.8M |
Fair-value level
| Fair-value level | % net assets | Value |
|---|---|---|
| Level 1 | 83.62% | $576M |
| Level 3 | 2.71% | $18.7M |
| Level 2 | 13.67% | $94.2M |
Level 3 = valued with unobservable inputs (typically private or illiquid).
Long / short
| Long / short | % net assets | Value |
|---|---|---|
| Long | 97.05% | $669M |
| N/A | 2.95% | $20.3M |
All allocation percentages use net assets as the denominator (N-PORT convention). A position's share of invested assets may differ from its share of the whole fund including cash and leverage.
All 131 positions
| Security | Identifier | Type | Issuer | Country | Balance | Units | Value (USD) | Weight | FV level |
|---|---|---|---|---|---|---|---|---|---|
| uniQure NV | NL0010696654 | Equity | CORP | Netherlands | 792,575 | shares | $36.5M | 5.30% | 1 |
| AstraZeneca PLC | GB0009895292 | Equity | CORP | United Kingdom | 145,278 | shares | $27.5M | 4.00% | 1 |
| VeraDermics Inc | 922967104 | Equity | CORP | United States | 193,541 | shares | $23.8M | 3.45% | 1 |
| Abivax SA | 00370M103 | Equity | CORP | France | 169,508 | shares | $22.6M | 3.28% | 1 |
| Sanofi SA | 80105N105 | Equity | CORP | France | 471,254 | shares | $20.1M | 2.92% | 1 |
| VERADERMICS, INC. | — | Preferred | CORP | United States | 148,342 | shares | $18.2M | 2.65% | 1 |
| Argenx SE | 04016X101 | Equity | CORP | Netherlands | 19,265 | shares | $17.9M | 2.59% | 1 |
| Novo Nordisk A/S | 670100205 | Equity | CORP | Denmark | 367,740 | shares | $17.6M | 2.56% | 1 |
| Abbott Laboratories | 002824100 | Equity | CORP | United States | 182,305 | shares | $16.5M | 2.40% | 1 |
| UnitedHealth Group Inc | 91324P102 | Equity | CORP | United States | 38,128 | shares | $15.8M | 2.30% | 1 |
| Medtronic PLC | IE00BTN1Y115 | Equity | CORP | Ireland | 190,766 | shares | $14.9M | 2.17% | 1 |
| Roche Holding AG | 771195104 | Equity | CORP | Switzerland | 279,410 | shares | $14.3M | 2.08% | 1 |
| Danaher Corp | 235851102 | Equity | CORP | United States | 74,859 | shares | $14.3M | 2.07% | 1 |
| Thermo Fisher Scientific Inc | 883556102 | Equity | CORP | United States | 28,268 | shares | $14.2M | 2.06% | 1 |
| Alcon AG | CH0432492467 | Equity | CORP | Switzerland | 202,865 | shares | $13.6M | 1.98% | 2 |
| Newamsterdam Pharma Co NV | NL00150012L7 | Equity | CORP | Netherlands | 382,193 | shares | $13M | 1.88% | 1 |
| OXB | GB00BDFBVT43 | Equity | CORP | United Kingdom | 1,478,680 | shares | $12.2M | 1.78% | 1 |
| Intuitive Surgical Inc | 46120E602 | Equity | CORP | United States | 30,687 | shares | $12.2M | 1.77% | 1 |
| Merck & Co Inc | 58933Y105 | Equity | CORP | United States | 93,962 | shares | $12.1M | 1.75% | 1 |
| ProQR Therapeutics NV | NL0010872495 | Equity | CORP | Netherlands | 6,307,646 | shares | $11.7M | 1.70% | 1 |
| Boston Scientific Corp | 101137107 | Equity | CORP | United States | 270,298 | shares | $11.5M | 1.67% | 1 |
| Praxis Precision Medicines Inc | 74006W207 | Equity | CORP | United States | 32,827 | shares | $11M | 1.59% | 1 |
| Ventas Inc | 92276F100 | Equity | OTHER | United States | 113,939 | shares | $10.1M | 1.47% | 1 |
| IMMUNIC | — | Equity deriv. | OTHER | United States | 777,587 | shares | $9.5M | 1.39% | 1 |
| Lonza Group AG | CH0013841017 | Equity | CORP | Switzerland | 14,055 | shares | $9.5M | 1.38% | 2 |
| Structure Therapeutics Inc | 86366E106 | Equity | CORP | Cayman Islands | 176,459 | shares | $9.5M | 1.37% | 1 |
| Welltower Inc | 95040Q104 | Equity | OTHER | United States | 40,285 | shares | $9.1M | 1.33% | 1 |
| Precision BioSciences Inc | 74019P207 | Equity | CORP | United States | 1,144,208 | shares | $9M | 1.31% | 1 |
| CVS Health Corp | 126650100 | Equity | CORP | United States | 83,357 | shares | $8.6M | 1.25% | 1 |
| Humana Inc | 444859102 | Equity | CORP | United States | 21,487 | shares | $8.5M | 1.24% | 1 |
| IMMUNIC INC. | — | Equity deriv. | OTHER | United States | 621,786 | shares | $8.5M | 1.23% | 1 |
| Charles River Laboratories International Inc | 159864107 | Equity | CORP | United States | 30,525 | shares | $6.9M | 1.00% | 1 |
| Bayer AG | DE000BAY0017 | Equity | CORP | Germany | 121,869 | shares | $6.7M | 0.98% | 2 |
| Insulet Corp | 45784P101 | Equity | CORP | United States | 40,331 | shares | $6.1M | 0.89% | 1 |
| Zai Lab Ltd | 98887Q104 | Equity | CORP | Cayman Islands | 311,294 | shares | $5.9M | 0.86% | 1 |
| UNITEDHEALTH GROUP INC | 91324PEJ7 | Debt | CORP | United States | 6,060,000 | principal | $5.9M | 0.86% | 2 |
| Oculis Holding AG | CH1242303498 | Equity | CORP | Switzerland | 417,714 | shares | $5.8M | 0.84% | 1 |
| ABBOTT LABORATORIES | 002824BG4 | Debt | CORP | United States | 5,652,000 | principal | $5.5M | 0.80% | 2 |
| IQVIA Holdings Inc | 46266C105 | Equity | CORP | United States | 28,419 | shares | $5.5M | 0.80% | 1 |
| ICON PLC | IE0005711209 | Equity | CORP | Ireland | 30,658 | shares | $5.3M | 0.77% | 1 |
| Disc Medicine Inc | 254604101 | Equity | CORP | United States | 71,985 | shares | $5.3M | 0.76% | 1 |
| PFIZER INC | 717081ET6 | Debt | CORP | United States | 5,300,000 | principal | $5.2M | 0.75% | 2 |
| Healthpeak Properties Inc | 42250P103 | Equity | OTHER | United States | 241,545 | shares | $5.2M | 0.75% | 1 |
| ALPHA 9 ONCOLOGYrestricted | — | Preferred | CORP | United States | 2,871,748 | shares | $5M | 0.73% | 3 |
| RADIANT BIOTHERAPEUTICS INC.restricted | — | Preferred | CORP | United States | 1,147,236 | shares | $5M | 0.73% | 3 |
| GeneDx Holdings Corp | 81663L200 | Equity | CORP | United States | 71,515 | shares | $4.9M | 0.71% | 1 |
| Abivax SA | FR0012333284 | Equity | CORP | France | 37,000 | shares | $4.9M | 0.71% | 2 |
| State Street Global Advisors | 857492706 | Short-term inv. | RF | United States | 4,792,264 | shares | $4.8M | 0.70% | 1 |
| Oxford Nanopore Technologies PLC | GB00BP6S8Z30 | Equity | CORP | United Kingdom | 2,891,768 | shares | $4.8M | 0.69% | 1 |
| Immatics NV | NL0015285941 | Equity | CORP | Netherlands | 466,940 | shares | $4.7M | 0.69% | 1 |
| ZIMMER BIOMET HOLDINGS | 98956PAG7 | Debt | CORP | United States | 5,000,000 | principal | $4.6M | 0.67% | 2 |
| Inventiva SACA | 46124U107 | Equity | CORP | France | 1,214,281 | shares | $4.6M | 0.67% | 1 |
| Elevance Health Inc | 036752103 | Equity | CORP | United States | 11,744 | shares | $4.5M | 0.66% | 1 |
| WuXi XDC Cayman Inc | KYG9808A1058 | Equity | CORP | Cayman Islands | 601,000 | shares | $4.4M | 0.64% | 2 |
| JOHNSON & JOHNSON | 478160BV5 | Debt | CORP | United States | 5,470,000 | principal | $4.4M | 0.63% | 2 |
| AgomAb Therapeutics NV | 00860C102 | Equity | CORP | Belgium | 312,731 | shares | $4.1M | 0.59% | 1 |
| Waters Corp | 941848103 | Equity | CORP | United States | 10,752 | shares | $4M | 0.59% | 1 |
| Orion Oyj | FI0009014377 | Equity | CORP | Finland | 43,708 | shares | $3.6M | 0.52% | 2 |
| Diaceutics Plc | GB00BJQTGV64 | Equity | CORP | United Kingdom | 1,841,064 | shares | $3.6M | 0.52% | 1 |
| THERMO FISHER SCIENTIFIC | 883556CY6 | Debt | CORP | United States | 3,500,000 | principal | $3.5M | 0.50% | 2 |
| Omega Healthcare Investors Inc | 681936100 | Equity | OTHER | United States | 71,075 | shares | $3.4M | 0.49% | 1 |
| Molina Healthcare Inc | 60855R100 | Equity | CORP | United States | 14,253 | shares | $3.3M | 0.47% | 1 |
| ROCHE HOLDINGS INC | 771196BX9 | Debt | CORP | United States | 3,600,000 | principal | $3.2M | 0.46% | 2 |
| Inspire Medical Systems Inc | 457730109 | Equity | CORP | United States | 70,089 | shares | $3.1M | 0.45% | 1 |
| McKesson Corp | 58155Q103 | Equity | CORP | United States | 4,102 | shares | $3.1M | 0.45% | 1 |
| ABBVIE INC | 00287YAR0 | Debt | CORP | United States | 3,200,000 | principal | $3.1M | 0.45% | 2 |
| Healthcare Realty Trust Inc | 42226K105 | Equity | OTHER | United States | 152,505 | shares | $3.1M | 0.45% | 1 |
| Zoetis Inc | 98978V103 | Equity | CORP | United States | 40,851 | shares | $2.9M | 0.43% | 1 |
| ELEVANCE HEALTH INC | 036752AP8 | Debt | CORP | United States | 3,200,000 | principal | $2.9M | 0.42% | 2 |
| CIGNA GROUP/THE | 125523CM0 | Debt | CORP | United States | 3,200,000 | principal | $2.9M | 0.42% | 2 |
| Jazz Pharmaceuticals PLC | IE00B4Q5ZN47 | Equity | CORP | Ireland | 11,844 | shares | $2.9M | 0.41% | 1 |
| Dexcom Inc | 252131107 | Equity | CORP | United States | 42,251 | shares | $2.8M | 0.41% | 1 |
| CareDx Inc | 14167L103 | Equity | CORP | United States | 96,034 | shares | $2.7M | 0.40% | 1 |
| Stryker Corp | 863667101 | Equity | CORP | United States | 8,490 | shares | $2.7M | 0.39% | 1 |
| Sabra Health Care REIT Inc | 78573L106 | Equity | OTHER | United States | 136,559 | shares | $2.7M | 0.39% | 1 |
| Maze Therapeutics Inc | 578784100 | Equity | CORP | United States | 84,992 | shares | $2.5M | 0.37% | 1 |
| Perceptive Capital Solutions Corp | KYG700771051 | Equity | CORP | Cayman Islands | 223,118 | shares | $2.4M | 0.35% | 1 |
| SpyGlass Pharma Inc | 85220G109 | Equity | CORP | United States | 108,188 | shares | $2.4M | 0.35% | 1 |
| CRYSTALYS THERAPEUTICS SER Arestricted | — | Preferred | CORP | United States | 2,215,900 | shares | $2.2M | 0.32% | 3 |
| CVS HEALTH CORP | 126650DQ0 | Debt | CORP | United States | 2,448,000 | principal | $2.1M | 0.31% | 2 |
| Ascendis Pharma A/S | DK0060615755 | Equity | CORP | Denmark | 8,031 | shares | $2.1M | 0.31% | 1 |
| Teva Pharmaceutical Industries Ltd | 881624209 | Equity | CORP | Israel | 62,726 | shares | $2.1M | 0.31% | 1 |
| ENDEAVOR BIOMEDICINES, INC.restricted | — | Preferred | CORP | United States | 424,079 | shares | $2M | 0.29% | 3 |
| ATALANTA THERAPEUTICSrestricted | — | Preferred | CORP | United States | 2,517,092 | shares | $2M | 0.29% | 3 |
| Mobia Medical Inc | 60705V103 | Equity | CORP | United States | 141,126 | shares | $1.9M | 0.27% | 1 |
| Alkermes PLC | IE00B56GVS15 | Equity | CORP | Ireland | 35,087 | shares | $1.8M | 0.27% | 1 |
| Hangzhou Tigermed Consulting Co Ltdrestricted | CNE1000040M1 | Equity | CORP | China | 411,500 | shares | $1.8M | 0.27% | 2 |
| PRECISION BIOSCIENCES | — | Equity deriv. | OTHER | United States | 396,233 | shares | $1.8M | 0.26% | 1 |
| Becton Dickinson & Co | 075887109 | Equity | CORP | United States | 11,731 | shares | $1.8M | 0.26% | 1 |
| MEDTRONIC INC | 585055BT2 | Debt | CORP | United States | 1,675,000 | principal | $1.6M | 0.23% | 2 |
| AMOLYT MILESTONErestricted | — | Preferred | CORP | United States | 9,785 | shares | $1.5M | 0.22% | 3 |
| ABBVIE INC | 00287YAW9 | Debt | CORP | United States | 1,705,000 | principal | $1.5M | 0.21% | 2 |
| Seaport Therapeutics Inc | 81221K108 | Equity | CORP | United States | 56,795 | shares | $1.2M | 0.18% | 1 |
| Revolution Medicines Inc | 76155X100 | Equity | CORP | United States | 5,721 | shares | $1.1M | 0.16% | 1 |
| OSE Immuno | FR0012127173 | Equity | CORP | France | 275,416 | shares | $982K | 0.14% | 2 |
| GLAXOSMITHKLINE CAPITAL | 377373AH8 | Debt | CORP | United Kingdom | 1,000,000 | principal | $974K | 0.14% | 2 |
| DH EUROPE FINANCE II | 23291KAJ4 | Debt | CORP | Luxembourg | 985,000 | principal | $791K | 0.11% | 2 |
| Immunic Inc | 4525EP200 | Equity | CORP | United States | 47,625 | shares | $732K | 0.11% | 1 |
| Sandoz Group AG | 799926100 | Equity | CORP | Switzerland | 7,614 | shares | $689K | 0.10% | 1 |
| LivaNova PLC | GB00BYMT0J19 | Equity | CORP | United Kingdom | 7,817 | shares | $643K | 0.09% | 1 |
| Odyssey Therapeutics Inc | 67613T104 | Equity | CORP | United States | 30,525 | shares | $571K | 0.08% | 1 |
| Kailera Therapeutics Inc | 482931102 | Equity | CORP | United States | 25,455 | shares | $561K | 0.08% | 1 |
| Renalytix PLCrestricted | GB00BYWL4Y04 | Equity | CORP | United Kingdom | 17,802,728 | shares | $543K | 0.08% | 1 |
| ENDEAVOR BIOMEDICINES INC.restricted | — | Preferred | CORP | United States | 78,308 | shares | $511K | 0.07% | 3 |
| InspireMD Inc | 45779A846 | Equity | CORP | United States | 695,460 | shares | $487K | 0.07% | 1 |
| ENGRAIL THERAPEUTICS INC. SERIrestricted | — | Preferred | CORP | United States | 897,073 | shares | $430K | 0.06% | 3 |
| Avalyn Pharma Inc | 05348Y105 | Equity | CORP | United States | 12,390 | shares | $408K | 0.06% | 1 |
| Hemab Therapeutics Holdings Inc | 423494103 | Equity | CORP | United States | 9,677 | shares | $355K | 0.05% | 1 |
| Deutsche Bank AG | — | FX deriv. | OTHER | United States | 2 | contracts | $275K | 0.04% | 2 |
| Goldman Sachs International | — | FX deriv. | OTHER | United States | 1 | contracts | $197K | 0.03% | 2 |
| Quoin Pharmaceuticals Ltd | 74907L409 | Equity | CORP | Israel | 40,400 | shares | $196K | 0.03% | 1 |
| OCULIS HOLDINGS AG | — | Equity | CORP | United States | 11,538 | shares | $160K | 0.02% | 1 |
| Morgan Stanley & Co. International PLC | — | FX deriv. | OTHER | United States | 1 | contracts | $73.4K | 0.01% | 2 |
| Citibank NA | — | FX deriv. | OTHER | United States | 1 | contracts | $42.3K | 0.01% | 2 |
| SHIRE ACQ INV IRELAND DA | 82481LAD1 | Debt | CORP | Ireland | 35,000 | principal | $34.9K | 0.01% | 2 |
| Royal Bank of Canada | — | FX deriv. | OTHER | XX | 1 | contracts | $18.1K | 0.00% | 2 |
| Morgan Stanley & Co. International PLC | — | FX deriv. | OTHER | United States | 1 | contracts | $11.5K | 0.00% | 2 |
| Standard Chartered Bank | — | FX deriv. | OTHER | United States | 2 | contracts | $8.9K | 0.00% | 2 |
| CONTRA FUSION PHARMACErestricted | 361CVR012 | Equity deriv. | OTHER | Canada | 3,689 | shares | $5.1K | 0.00% | 3 |
| Morgan Stanley & Co. International PLC | — | FX deriv. | OTHER | United States | 1 | contracts | $46 | 0.00% | 2 |
| PRIOTHERA LIMITEDrestricted | — | Preferred | CORP | Ireland | 194,134 | shares | $22 | 0.00% | 3 |
| IO LIGHT HOLDINIGS, INC.restricted | — | Preferred | CORP | United States | 101,839 | shares | $10 | 0.00% | 3 |
| ESC CB144A MALLINCKROD | 561ESCAK0 | Debt | CORP | United States | 997,897 | principal | $0 | 0.00% | 3 |
| Options Clearing Corp. | — | Equity deriv. | OTHER | United States | -70 | contracts | $-59.9K | -0.01% | 1 |
| Royal Bank of Canada | — | FX deriv. | OTHER | Denmark | 1 | contracts | $-15.6K | -0.00% | 2 |
| Standard Chartered Bank | — | FX deriv. | OTHER | United Kingdom | 1 | contracts | $-8K | -0.00% | 2 |
| Goldman Sachs International | — | FX deriv. | OTHER | Israel | 1 | contracts | $-7.4K | -0.00% | 2 |
| Royal Bank of Canada | — | FX deriv. | OTHER | United States | 1 | contracts | $-5.5K | -0.00% | 2 |
| Morgan Stanley & Co. International PLC | — | FX deriv. | OTHER | United States | 1 | contracts | $-4.6K | -0.00% | 2 |
| Standard Chartered Bank | — | FX deriv. | OTHER | United States | 1 | contracts | $-2.2K | -0.00% | 2 |
| Goldman Sachs International | — | FX deriv. | OTHER | United States | 1 | contracts | $-182 | -0.00% | 2 |
Equities show share counts; bonds and loans show principal amount. Coupon, maturity and ratings are shown where the filing discloses them. Source: SEC N-PORT via market-data vendor re-serve, position-level.
Holdings reports on file
| Report date | Filed | Positions | Σ weight | Net assets (calc.) | Coverage |
|---|---|---|---|---|---|
| Jun 30, 2026 | Aug 28, 2026 | 131 | 100.0% | $689M | full |
| Mar 31, 2026 | May 29, 2026 | 120 | 100.0% | $599M | full |
| Dec 31, 2025 | Feb 27, 2026 | 119 | 100.0% | $648M | full |
Net assets here are calculated from position values ÷ reported weights (median across positions), not a reported figure.
CEF Explorer research page for abrdn World Healthcare Fund. Figures carry their own dates and sources; a discount to NAV does not guarantee convergence or any return. This is not investment advice.